vs
Gitlab Inc.（GTLB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Gitlab Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$244.4M vs $207.3M），Gitlab Inc.净利率更高（-3.4% vs -62.0%，领先58.6%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 24.6%），Gitlab Inc.自由现金流更多（$28.4M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 22.1%）
GitLab Inc.是一家美国企业，开发并运营同名开放核心架构DevOps软件平台，覆盖软件开发、安全防护、运维运营全流程。产品基于Git分布式版本控制技术搭建，还为各项目提供访问控制、缺陷追踪、需求管理、任务调度、项目知识库、代码片段分享等全栈协作功能。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
GTLB vs RARE — 直观对比
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $244.4M | $207.3M |
| 净利润 | $-8.3M | $-128.6M |
| 毛利率 | 86.8% | — |
| 营业利润率 | -5.1% | -54.7% |
| 净利率 | -3.4% | -62.0% |
| 营收同比 | 24.6% | 25.9% |
| 净利润同比 | -128.0% | 3.5% |
| 每股收益（稀释后） | $-0.05 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $244.4M | $207.3M | ||
| Q3 25 | $236.0M | $159.9M | ||
| Q2 25 | $214.5M | $166.5M | ||
| Q1 25 | $211.4M | $139.3M | ||
| Q4 24 | $196.0M | $164.6M | ||
| Q3 24 | $182.6M | $139.5M | ||
| Q2 24 | $169.2M | $147.0M | ||
| Q1 24 | $163.8M | $108.8M |
| Q4 25 | $-8.3M | $-128.6M | ||
| Q3 25 | $-9.2M | $-180.4M | ||
| Q2 25 | $-35.9M | $-115.0M | ||
| Q1 25 | $5.8M | $-151.1M | ||
| Q4 24 | $29.6M | $-133.2M | ||
| Q3 24 | $12.9M | $-133.5M | ||
| Q2 24 | $-54.6M | $-131.6M | ||
| Q1 24 | $-36.5M | $-170.7M |
| Q4 25 | 86.8% | — | ||
| Q3 25 | 87.9% | — | ||
| Q2 25 | 88.3% | — | ||
| Q1 25 | 89.2% | — | ||
| Q4 24 | 88.7% | — | ||
| Q3 24 | 88.3% | — | ||
| Q2 24 | 88.9% | — | ||
| Q1 24 | 90.2% | — |
| Q4 25 | -5.1% | -54.7% | ||
| Q3 25 | -7.8% | -106.9% | ||
| Q2 25 | -16.1% | -64.8% | ||
| Q1 25 | -9.1% | -102.6% | ||
| Q4 24 | -14.7% | -74.3% | ||
| Q3 24 | -22.5% | -94.6% | ||
| Q2 24 | -31.7% | -79.1% | ||
| Q1 24 | -21.3% | -151.9% |
| Q4 25 | -3.4% | -62.0% | ||
| Q3 25 | -3.9% | -112.8% | ||
| Q2 25 | -16.7% | -69.0% | ||
| Q1 25 | 2.7% | -108.5% | ||
| Q4 24 | 15.1% | -80.9% | ||
| Q3 24 | 7.1% | -95.7% | ||
| Q2 24 | -32.3% | -89.5% | ||
| Q1 24 | -22.3% | -156.8% |
| Q4 25 | $-0.05 | $-1.28 | ||
| Q3 25 | $-0.06 | $-1.81 | ||
| Q2 25 | $-0.22 | $-1.17 | ||
| Q1 25 | $0.05 | $-1.57 | ||
| Q4 24 | $0.18 | $-1.34 | ||
| Q3 24 | $0.08 | $-1.40 | ||
| Q2 24 | $-0.35 | $-1.52 | ||
| Q1 24 | $-0.23 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $224.2M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $922.7M | $-80.0M |
| 总资产 | $1.6B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $224.2M | $421.0M | ||
| Q3 25 | $261.4M | $202.5M | ||
| Q2 25 | $255.7M | $176.3M | ||
| Q1 25 | $227.6M | $127.1M | ||
| Q4 24 | $176.6M | $174.0M | ||
| Q3 24 | $438.6M | $150.6M | ||
| Q2 24 | $420.3M | $480.7M | ||
| Q1 24 | $288.0M | $112.3M |
| Q4 25 | $922.7M | $-80.0M | ||
| Q3 25 | $866.6M | $9.2M | ||
| Q2 25 | $808.3M | $151.3M | ||
| Q1 25 | $775.9M | $144.2M | ||
| Q4 24 | $724.7M | $255.0M | ||
| Q3 24 | $642.8M | $346.8M | ||
| Q2 24 | $567.8M | $432.4M | ||
| Q1 24 | $571.2M | $140.3M |
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.4B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.3B | $1.5B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $1.3B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $28.4M | $-100.8M |
| 自由现金流率自由现金流/营收 | 11.6% | -48.6% |
| 资本支出强度资本支出/营收 | 1.2% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $242.3M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $31.4M | $-99.8M | ||
| Q3 25 | $49.4M | $-91.4M | ||
| Q2 25 | $106.3M | $-108.3M | ||
| Q1 25 | $63.2M | $-166.5M | ||
| Q4 24 | $-177.0M | $-79.3M | ||
| Q3 24 | $11.7M | $-67.0M | ||
| Q2 24 | $38.1M | $-77.0M | ||
| Q1 24 | $24.9M | $-190.7M |
| Q4 25 | $28.4M | $-100.8M | ||
| Q3 25 | $46.5M | $-92.7M | ||
| Q2 25 | $105.4M | $-110.7M | ||
| Q1 25 | $62.1M | $-167.8M | ||
| Q4 24 | $-178.1M | $-79.5M | ||
| Q3 24 | $10.8M | $-68.6M | ||
| Q2 24 | $37.4M | $-79.0M | ||
| Q1 24 | $24.5M | $-193.9M |
| Q4 25 | 11.6% | -48.6% | ||
| Q3 25 | 19.7% | -58.0% | ||
| Q2 25 | 49.1% | -66.5% | ||
| Q1 25 | 29.4% | -120.5% | ||
| Q4 24 | -90.8% | -48.3% | ||
| Q3 24 | 5.9% | -49.2% | ||
| Q2 24 | 22.1% | -53.7% | ||
| Q1 24 | 15.0% | -178.2% |
| Q4 25 | 1.2% | 0.5% | ||
| Q3 25 | 1.2% | 0.8% | ||
| Q2 25 | 0.4% | 1.5% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | 0.5% | 0.1% | ||
| Q3 24 | 0.5% | 1.2% | ||
| Q2 24 | 0.4% | 1.4% | ||
| Q1 24 | 0.2% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 10.89× | — | ||
| Q4 24 | -5.99× | — | ||
| Q3 24 | 0.90× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTLB
| Subscription And Circulation | $146.4M | 60% |
| Subscription Software As A Service | $76.9M | 31% |
| License | $15.5M | 6% |
| Professional Services And Other | $5.6M | 2% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
